drugset / Trial / NCT01455883

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

NCT01455883

Phase 3 Withdrawn Intarcia Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.

Timeline

Start
2013-02
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 60 ug
Comparator Glimepiride Small molecule 8 mg Oral